A Study to Evaluate the Efficacy and Safety of PF-06700841 in Subjects With Active Psoriatic Arthritis
Launched by PFIZER · May 23, 2019
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Active arthritis at screening/baseline as indicated by \>/= 3 tender/painful and 3 swollen joints.
- • Active plaque psoriasis at screening and baseline.
- Exclusion Criteria:
- • Non-plaque forms of psoriasis (with exception of nail psoriasis).
- • History of autoimmune rheumatic disease other than PsA; also prior history of or current, rheumatic inflammatory disease other than PsA.
About Pfizer
Pfizer Inc. is a global leader in biopharmaceutical innovation, dedicated to discovering, developing, and delivering advanced therapies that enhance patient outcomes across a wide range of medical conditions. With a rich history of scientific research and a commitment to quality, Pfizer focuses on areas such as oncology, immunology, cardiology, and rare diseases. The company leverages cutting-edge technology and collaborates with healthcare professionals, regulatory bodies, and academic institutions to conduct rigorous clinical trials that ensure the safety and efficacy of its products. Pfizer's mission is to bring breakthroughs that change patients' lives, exemplifying its commitment to health and wellness worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Belgrade, , Serbia
Praha 2, , Czechia
Tallinn, , Estonia
Piestany, , Slovakia
Poznan, , Poland
Hlucin, , Czechia
Rimavska Sobota, , Slovakia
Tallinn, , Estonia
Budapest, , Hungary
Niska Banja, , Serbia
Maroochydore, Queensland, Australia
Nowa Sol, , Poland
Bialystok, , Poland
Nadarzyn, , Poland
Uherske Hradiste, , Czechia
Sevilla, , Spain
Yaroslavl, , Russian Federation
A Coruna, , Spain
Torun, , Poland
Saratov, , Russian Federation
Veszprem, , Hungary
Lublin, , Poland
Plovdiv, , Bulgaria
Warszawa, , Poland
Melbourne, Victoria, Australia
Santiago De Compostela, A Coruna, Spain
Praha 3, , Czechia
Pardubice, , Czechia
Sochaczew, , Poland
Tallinn, , Estonia
Plovdiv, , Bulgaria
Plovdiv, , Bulgaria
Sofia, , Bulgaria
Sofia, , Bulgaria
Sofia, , Bulgaria
Kaunas, , Lithuania
Vilnius, , Lithuania
Bialystok, , Poland
Poznan, , Poland
Korolev, Moscow Region, Russian Federation
Orenburg, , Russian Federation
Orenburg, , Russian Federation
Petrozavodsk, , Russian Federation
Ryazan, , Russian Federation
Ryazan, , Russian Federation
Saint Petersburg, , Russian Federation
Vladimir, , Russian Federation
Poprad, , Slovakia
Patients applied
Trial Officials
Pfizer CT.gov Call Center
Study Director
Pfizer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials